3H-吲哚-2-甲醛 | 104650-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3H-吲哚-2-甲醛
• 英文名称: 3H-indole-2-carboxaldehyde
• 英文别名: 3h-Indole-2-carbaldehyde
• CAS: 104650-47-7
• 化学式: C₉H₇NO
• 分子量: 145.161
• InChiKey: QNHDKWJSRNIEEW-UHFFFAOYSA-N

物化性质

• 沸点：
  292.2±43.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-nitrobenzenesulfonyl)-N-(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine 、 3H-吲哚-2-甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 以77%的产率得到N-[[4-[[1H-indol-2-ylmethyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]phenyl]methyl]-2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide
  参考文献：
  名称：

  Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication

  摘要：

  The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure activity relationship (SA R) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-Amethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 (125)I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 mu M. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.

  DOI：

  10.1021/jm100073m

文献信息

• Quinolinones as Inhibitors of Translation Initiation Complex
  申请人：Sanford-Burnham Medical Research Institute

  公开号：US20180044324A1

  公开（公告）日：2018-02-15

  Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

  本文提供了含喹啉酮的化合物和药物组合物。这些喹啉酮及其组合物可用作真核翻译起始因子4F（eIF4F）复合物调节剂。
• METHOD FOR PRODUCING NON-ISOCYANATE POLYURETHANES
  申请人：Henkel AG & Co. KGaA

  公开号：EP3677616A1

  公开（公告）日：2020-07-08

  The present application is directed to a method for producing non-isocyanate polyurethanes. More particularly, the application is directed to method for producing non-isocyanate polyurethanes by using a single catalyst component selected from an amidoindole derivative, a benzimidazole derivative and a squaramide derivative.

  本申请涉及一种生产非异氰酸酯聚氨酯的方法。更具体地说，本申请涉及使用选自氨基吲哚衍生物、苯并咪唑衍生物和方酰胺衍生物的单一催化剂组分生产非异氰酸酯聚氨酯的方法。
• Biodetection by nucleic acid-templated chemistry
  申请人：Coull M. James

  公开号：US20070154899A1

  公开（公告）日：2007-07-05

  The invention provides compositions and methods for the detection of biological targets, (e.g. nucleic acids and proteins) by nucleic acid templated chemistry, for example, by generating fluorescent, chemiluminescent and/or chromophoric signals.
• BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY
  申请人：Coull James M.

  公开号：US20130084561A1

  公开（公告）日：2013-04-04

  The invention provides compositions and methods for the detection of biological targets, (e.g. nucleic acids and proteins) by nucleic acid templated chemistry, for example, by generating fluorescent, chemiluminescent and/or chromophoric signals.
• Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication
  作者：Renato T. Skerlj、Gary J. Bridger、Al Kaller、Ernest J. McEachern、Jason B. Crawford、Yuanxi Zhou、Bem Atsma、Jonathon Langille、Susan Nan、Duane Veale、Trevor Wilson、Curtis Harwig、Sigrid Hatse、Katrien Princen、Erik De Clercq、Dominique Schols

  DOI：10.1021/jm100073m

  日期：2010.4.22

  The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure activity relationship (SA R) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-Amethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 (125)I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 mu M. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.